Tatyana Kutsy, MD
Internal Medicine · Bellevue, WANPI 1992807499
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.1% of the total across 474 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 38 manufacturers reported payments, led by AbbVie at 25.8% of the total. Among internal medicine clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 474 payments — averaging $27.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Johnson & Johnson$1K
- AstraZeneca$910
- Boehringer Ingelheim$875
- Amgen$745
- Astellas Pharma US Inc$643
- plus $5K from 32 others
What the payments were for
- Food & beverage$12,47696%
- Education$5104%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 119 | $3,355 |
| Johnson & Johnson | 38 | $1,023 |
| AstraZeneca | 30 | $910 |
| Boehringer Ingelheim | 32 | $875 |
| Amgen | 21 | $745 |
| Astellas Pharma US Inc | 13 | $643 |
| Kowa Pharmaceuticals America, Inc. | 18 | $606 |
| Novo Nordisk | 30 | $597 |
| Lilly USA, LLC | 17 | $596 |
| Pfizer | 18 | $386 |
| Phathom Pharmaceuticals, Inc. | 7 | $354 |
| Lundbeck LLC | 16 | $306 |
| Bayer | 6 | $263 |
| Nestle Healthcare Nutrition Inc. | 12 | $261 |
| Amarin Pharma, Inc. | 15 | $259 |
| Aimmune Therapeutics, Inc. | 12 | $248 |
| Teva Pharmaceuticals USA, Inc. | 5 | $182 |
| Sunovion Pharmaceuticals Inc. | 7 | $170 |
| Lexicon Pharmaceuticals, Inc. | 5 | $165 |
| Sanofi-aventis U.S. LLC | 4 | $126 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $125 |
| Ironwood Pharmaceuticals, Inc | 7 | $111 |
| Otsuka America Pharmaceutical, Inc. | 5 | $104 |
| Idorsia Pharmaceuticals US Inc | 5 | $85 |
| Eisai Inc. | 4 | $83 |
| GSK | 3 | $64 |
| Xeris Pharmaceuticals, Inc. | 3 | $64 |
| Merck | 3 | $44 |
| Boston Scientific | 2 | $38 |
| Esperion Therapeutics, Inc. | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Linus Health, Inc. | 1 | $26 |
| Azurity Pharmaceuticals, Inc. | 1 | $24 |
| Medtronic | 1 | $19 |
| Dexcom, Inc. | 1 | $19 |
| Ardelyx, Inc. | 1 | $18 |
| Hologic Sales And Service, LLC | 1 | $16 |
| VBI Vaccine (delaware) Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,986 in reported general payments places this provider in the 95th percentile of 2,038 internal medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 140 | $195,235 |
| FarxigaDapagliflozin Propanediol | 119 | $113,528 |
| EliquisApixaban | 129 | $92,072 |
| LinzessLinaclotide | 118 | $89,996 |
| OzempicSemaglutide | 82 | $81,844 |
| TrulicityDulaglutide | 48 | $57,300 |
| XareltoRivaroxaban | 61 | $52,896 |
| JardianceEmpagliflozin | 45 | $39,797 |
| JanuviaSitagliptin Phosphate | 23 | $28,941 |
| ProliaDenosumab | 15 | $26,513 |
| ZenpepLipase/Protease/Amylase | 26 | $23,280 |
| Diclofenac Sodium | 271 | $22,130 |
| InvokanaCanagliflozin | 19 | $17,796 |
| Lidocaine | 109 | $16,366 |
| MyrbetriqMirabegron | 24 | $15,628 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $3,355 | $285,232258 claims |
| AstraZenecaFarxiga, Brilinta | $910 | $121,674137 claims |
| Novo NordiskOzempic, Rybelsus, Levemir | $597 | $99,053109 claims |
| PfizerEliquis | $386 | $92,072129 claims |
| Johnson & JohnsonXarelto, Invokana | $1,023 | $70,69280 claims |
| Lilly USA, LLCTrulicity | $596 | $57,30048 claims |
| Boehringer IngelheimJardiance | $875 | $39,79745 claims |
| MerckJanuvia | $44 | $28,94123 claims |
| AmgenProlia | $745 | $26,51315 claims |
| Aimmune Therapeutics, Inc.Zenpep | $248 | $23,28026 claims |
| Astellas Pharma US IncMyrbetriq | $643 | $15,62824 claims |
| GSKBreo Ellipta, Arnuity Ellipta | $64 | $14,87634 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,038 internal medicine providers in Washington.
Other internal medicine in Bellevue
- Lawrence LoebBellevue$784K
- Gary SchusterBellevue$16K
- Peter ShalitSeattle$1M
- Shawna PurcellOlympia$294K
- Scott RamseySeattle$230K
- Michael CairnsSeattle$144K
- Peiqing QianSeattle$117K
- Alan KellySpokane Valley$96K
- Emily EgdaminWenatchee$81K
- Royce MorrisonTacoma$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.